Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-11-21
1999-04-06
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514211, 514356, 424452, 424455, A61K 3813, A61K 3155, A61K 3144, A61K 948
Patent
active
058918450
ABSTRACT:
Vitamin E TPGS/drug compositions and methods are provided which obviate the need for surfactants or non-evaporated co-solvents because the active drug component is dissolved directly into Vitamin E TPGS to form a true molecular solution--not an emulsion or a micro-emulsion. The invention provides a slowly dissolving TPGS/Drug matrix that absorbs gastrointestinal fluid into the matrix at the dosage form/fluid interface, where a gel-like liquid crystal is formed. This gel front forms a liquid crystal boundary where drug dissolution is highest. At this liquid crystal/GI fluid boundary, a synchronization takes place in which the rate of formation of liquid crystals equals the dissolution rate of liquid crystals at the water interface, thereby giving controlled order release of the drug into the GI tract. The rate of dissolution is also controlled by the geometry of the dosage form. The solid Vitamin E TPGS/drug matrices of the invention can be solidified and compressed into tablets or filled into capsules, with other excipients, binders and/or fillers. The solid TPGS/drug solution of the invention also can be made into an immediate release liquid formulation upon addition of water, or into a controlled release system solid tablet by the use of impermeable or semi-permeable barriers or coatings surrounding portions of the tablet.
REFERENCES:
patent: 3867521 (1975-02-01), Miskel et al.
patent: 4944949 (1990-07-01), Story et al.
patent: 5342625 (1994-08-01), Hauer et al.
patent: 5430017 (1995-07-01), Antalne et al.
patent: 5583105 (1996-12-01), Kovacs et al.
Sheu et al, Derwent Drug File Abstracts, abstract No. 96-18846, 1995.
Wu et al, Derwent Drug File Abstracts, abstract No. 95-05631, 1994.
Chi et al, Derwent Drug File Abstracts, abstract No. 96-20886, 1995.
MSDS Brochure: "Eastman Vitamin E TPGS (d-Alpha-Tocopheryl Polyethylene Glycol 1000 Succinate)", 1994.
Valantine et al., Recent Advances in Cardiac Transplantation, N. Engl. J. Med. 1995; vol. 333, No. 10, pp. 660-661.
Sokol et al., Improvement of Cyclosporin Absorption in Children After Liver Transplantation by Means of Water-Soluble Vitamin E, The Lancet, vol. 338: Jul. 27, 1991, pp. 212-215.
Robbins et al., Safe Coadministration of Terbinafine and Terfenadine: a Placebo-Controlled Crossover Study of Pharmacokinetic and Pharmacodynamic Interactions in Healthy Volunteers, Clinical Pharmacology & Therapeutics, vol. 59, No.3(Mar. 1996), pp. 275-283.
Fuisz Technologies Ltd.
Jarvis William R. A.
LandOfFree
Drug delivery systems utilizing liquid crystal structures does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug delivery systems utilizing liquid crystal structures, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug delivery systems utilizing liquid crystal structures will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1371399